Symbols / MNPR $53.71 -2.58% Monopar Therapeutics Inc.

Healthcare • Biotechnology • United States • NCM
MNPR Chart
About

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 359.43M
Enterprise Value 228.69M Income -13.72M Sales —
Book/sh 20.59 Cash/sh 20.98 Dividend Yield —
Payout 0.00% Employees — IPO —
P/E — Forward P/E -15.92 PEG —
P/S — P/B 2.61 P/C —
EV/EBITDA — EV/Sales — Quick Ratio 51.33
Current Ratio 51.35 Debt/Eq 0.11 LT Debt/Eq —
EPS (ttm) -1.85 EPS next Y -3.37 EPS Growth —
Revenue Growth — Earnings 2026-05-12 ROA -10.39%
ROE -14.22% ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 6.69M
Shs Float 4.40M Short Float 65.83% Short Ratio 9.56
Short Interest — 52W High 105.00 52W Low 26.05
Beta — Avg Volume 237.75K Volume 133.20K
Target Price $112.79 Recom Strong_buy Prev Close $55.13
Price $53.71 Change -2.58%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$112.79
Mean price target
2. Current target
$53.68
Latest analyst target
3. DCF / Fair value
$-34.82
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$53.68
Low
$100.00
High
$130.00
Mean
$112.79

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-03-30 main Chardan Capital Buy → Buy $100
2026-02-23 reit BTIG Buy → Buy $104
2026-02-02 reit BTIG Buy → Buy $104
2026-01-29 main Chardan Capital Buy → Buy $100
2026-01-14 reit BTIG Buy → Buy $104
2026-01-09 init Morgan Stanley — → Overweight $115
2025-11-14 down Raymond James Strong Buy → Outperform $123
2025-11-13 main Chardan Capital Buy → Buy $100
2025-11-10 init Leerink Partners — → Outperform $115
2025-11-09 main Chardan Capital Buy → Buy $100
2025-10-13 init Barclays — → Overweight $125
2025-10-06 main Raymond James Strong Buy → Strong Buy $142
2025-10-02 main Oppenheimer Outperform → Outperform $115
2025-09-29 main HC Wainwright & Co. Buy → Buy $105
2025-09-25 main Piper Sandler Overweight → Overweight $95
2025-09-25 main BTIG Buy → Buy $104
2025-09-25 main Chardan Capital Buy → Buy $85
2025-09-23 init Lake Street — → Buy $106
2025-09-16 main Chardan Capital Buy → Buy $60
2025-09-15 reit BTIG Buy → Buy $87
News
RSS: Latest MNPR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-03-31 ROBINSON CHANDLER D Chief Executive Officer — 6,732 — —
2026-03-31 CITTADINE ANDREW Chief Operating Officer — 3,514 — —
2025-12-31 ROBINSON CHANDLER D Chief Executive Officer — 8,724 — —
2025-12-31 CITTADINE ANDREW Chief Operating Officer — 4,326 — —
2025-12-26 VU QUAN ANH Chief Financial Officer — 1,500 $69.95 $104,925
2025-12-18 KLAUSNER ARTHUR J Director — 5,121 $67.06 $343,889
2025-09-30 ROBINSON CHANDLER D Chief Executive Officer — 8,726 — —
2025-09-30 CITTADINE ANDREW Chief Operating Officer — 4,327 — —
2025-09-24 TACTIC PHARMA, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 550,229 $63.61 $34,999,957
2025-07-14 STARR CHRISTOPHER M Director — 16,800 $40.00 $672,020
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
16.70
+3.36%
16.16
+83.01%
8.83
-16.19%
10.54
Research And Development
9.90
-23.85%
13.01
+132.24%
5.60
-26.23%
7.59
Selling General And Administration
6.80
+115.49%
3.16
-2.33%
3.23
+9.70%
2.95
General And Administrative Expense
6.80
+115.49%
3.16
-2.33%
3.23
+9.70%
2.95
Other Gand A
6.80
+115.49%
3.16
-2.33%
3.23
+9.70%
2.95
Total Expenses
16.70
+3.36%
16.16
+83.01%
8.83
-16.19%
10.54
Operating Income
-16.70
-3.36%
-16.16
-83.01%
-8.83
+16.19%
-10.54
Total Operating Income As Reported
-16.70
-3.36%
-16.16
-83.01%
-8.83
+16.19%
-10.54
EBITDA
-16.70
-3.36%
-16.16
-83.01%
-8.83
+16.19%
-10.54
Normalized EBITDA
-16.70
-3.36%
-16.16
-83.01%
-8.83
+16.19%
-10.54
EBIT
-16.70
-3.36%
-16.16
-83.01%
-8.83
+16.19%
-10.54
Total Unusual Items
—
—
—
—
Total Unusual Items Excluding Goodwill
—
—
—
—
Special Income Charges
—
—
—
—
Net Income
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Pretax Income
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Net Non Operating Interest Income Expense
2.99
+639.45%
0.40
-5.83%
0.43
+1920.05%
0.02
Net Interest Income
2.99
+639.45%
0.40
-5.83%
0.43
+1920.05%
0.02
Interest Income Non Operating
2.99
+639.45%
0.40
-5.83%
0.43
+1920.05%
0.02
Interest Income
2.99
+639.45%
0.40
-5.83%
0.43
+1920.05%
0.02
Other Income Expense
—
0.17
—
—
Other Non Operating Income Expenses
—
0.17
—
—
Tax Rate For Calcs
0.00
0.00
-100.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Net Income From Continuing Operation Net Minority Interest
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Net Income From Continuing And Discontinued Operation
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Net Income Continuous Operations
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Normalized Income
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Net Income Common Stockholders
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Diluted EPS
-1.85
+54.99%
-4.11
-35.20%
-3.04
+26.75%
-4.15
Basic EPS
-1.85
+54.99%
-4.11
-35.20%
-3.04
+26.75%
-4.15
Basic Average Shares
7.41
+95.53%
3.79
+37.09%
2.76
+8.69%
2.54
Diluted Average Shares
7.41
+95.53%
3.79
+37.09%
2.76
+8.69%
2.54
Diluted NI Availto Com Stockholders
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
140.72
+133.40%
60.29
+720.83%
7.35
-44.47%
13.23
Current Assets
140.46
+132.97%
60.29
+722.24%
7.33
-44.31%
13.17
Cash Cash Equivalents And Short Term Investments
140.40
+133.17%
60.21
+728.68%
7.27
-44.62%
13.12
Cash And Cash Equivalents
61.83
+34.96%
45.82
+530.55%
7.27
-11.24%
8.19
Other Short Term Investments
78.57
+445.75%
14.40
0.00
-100.00%
4.93
Other Current Assets
0.06
-19.18%
0.08
+18.72%
0.07
+44.48%
0.05
Total Non Current Assets
0.25
0.00
-100.00%
0.01
-79.35%
0.06
Net PPE
0.25
0.00
-100.00%
0.01
-79.35%
0.06
Gross PPE
0.25
0.00
-100.00%
0.01
-79.35%
0.06
Properties
—
—
0.00
0.00
Buildings And Improvements
—
—
0.01
-79.35%
0.06
Other Properties
0.25
—
0.01
-79.35%
0.06
Total Liabilities Net Minority Interest
2.89
-44.99%
5.25
+198.98%
1.76
-43.98%
3.14
Current Liabilities
2.74
-47.94%
5.25
+198.98%
1.76
-43.83%
3.13
Payables And Accrued Expenses
2.74
-47.94%
5.25
+198.98%
1.76
-43.83%
3.13
Payables
2.74
+21.33%
2.25
+28.28%
1.76
-43.83%
3.13
Accounts Payable
2.74
+21.33%
2.25
+28.28%
1.76
-43.83%
3.13
Current Accrued Expenses
0.00
-100.00%
3.00
0.00
—
Total Non Current Liabilities Net Minority Interest
0.15
0.00
0.00
-100.00%
0.01
Long Term Debt And Capital Lease Obligation
0.15
0.00
0.00
-100.00%
0.01
Long Term Capital Lease Obligation
0.15
0.00
0.00
-100.00%
0.01
Stockholders Equity
137.83
+150.43%
55.04
+884.95%
5.59
-44.62%
10.09
Common Stock Equity
137.83
+150.43%
55.04
+884.95%
5.59
-44.62%
10.09
Capital Stock
0.01
+9.65%
0.01
+104.73%
0.00
-76.98%
0.01
Common Stock
0.01
+9.65%
0.01
+104.73%
0.00
-76.98%
0.01
Share Issued
6.69
+9.66%
6.10
+104.72%
2.98
+15.12%
2.59
Ordinary Shares Number
6.69
+9.66%
6.10
+104.72%
2.98
+15.12%
2.59
Additional Paid In Capital
227.20
+73.72%
130.79
+98.75%
65.81
+6.36%
61.87
Retained Earnings
-89.51
-18.10%
-75.79
-25.89%
-60.21
-16.22%
-51.80
Gains Losses Not Affecting Retained Earnings
0.13
+265.05%
0.04
+354.68%
-0.01
-258.04%
0.01
Other Equity Adjustments
0.13
+265.05%
0.04
+354.68%
-0.01
-258.04%
0.01
Total Equity Gross Minority Interest
137.83
+150.43%
55.04
+884.95%
5.59
-44.62%
10.09
Total Capitalization
137.83
+150.43%
55.04
+884.95%
5.59
-44.62%
10.09
Working Capital
137.73
+150.25%
55.04
+887.19%
5.58
-44.45%
10.04
Invested Capital
137.83
+150.43%
55.04
+884.95%
5.59
-44.62%
10.09
Total Debt
0.15
0.00
0.00
-100.00%
0.01
Capital Lease Obligations
0.15
0.00
0.00
-100.00%
0.01
Net Tangible Assets
137.83
+150.43%
55.04
+884.95%
5.59
-44.62%
10.09
Tangible Book Value
137.83
+150.43%
55.04
+884.95%
5.59
-44.62%
10.09
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-12.20
-90.52%
-6.40
+18.50%
-7.86
-8.71%
-7.23
Cash Flow From Continuing Operating Activities
-12.20
-90.52%
-6.40
+18.50%
-7.86
-8.71%
-7.23
Net Income From Continuing Operations
-13.72
+11.99%
-15.59
-85.50%
-8.40
+20.10%
-10.52
Other Non Cash Items
—
4.55
—
—
Stock Based Compensation
4.84
+324.08%
1.14
-39.89%
1.90
+15.63%
1.64
Change In Working Capital
-2.61
-174.49%
3.50
+358.37%
-1.35
-182.27%
1.65
Change In Payables And Accrued Expense
-2.61
-174.48%
3.51
+362.97%
-1.33
-190.21%
1.48
Change In Accrued Expense
-3.00
-200.00%
3.00
0.00
—
Change In Payable
0.39
-23.40%
0.51
+138.00%
-1.33
-190.21%
1.48
Change In Account Payable
0.39
-23.40%
0.51
+138.00%
-1.33
-190.21%
1.48
Change In Other Working Capital
-0.01
-322.56%
0.00
—
-0.00
Change In Other Current Assets
0.02
+220.57%
-0.01
+37.40%
-0.02
-111.88%
0.17
Investing Cash Flow
-63.45
-342.54%
-14.34
-390.97%
4.93
+200.19%
-4.92
Cash Flow From Continuing Investing Activities
-63.45
-342.54%
-14.34
-390.97%
4.93
+200.19%
-4.92
Net Investment Purchase And Sale
-63.45
-342.54%
-14.34
-390.97%
4.93
+200.19%
-4.92
Purchase Of Investment
-87.15
-468.73%
-15.32
-94.42%
-7.88
-60.25%
-4.92
Sale Of Investment
23.70
+2304.31%
0.99
-92.30%
12.81
0.00
Financing Cash Flow
91.57
+54.45%
59.29
+2824.80%
2.03
+6066.85%
0.03
Cash Flow From Continuing Financing Activities
91.57
+54.45%
59.29
+2824.80%
2.03
+6066.85%
0.03
Net Issuance Payments Of Debt
—
—
—
—
Issuance Of Debt
—
—
—
—
Long Term Debt Issuance
—
—
—
—
Net Long Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
92.14
+55.13%
59.40
+2763.59%
2.07
+1797.07%
0.11
Common Stock Payments
-35.00
0.00
—
—
Repurchase Of Capital Stock
-35.00
0.00
—
—
Proceeds From Stock Option Exercised
0.57
+672722.62%
0.00
0.00
-100.00%
0.00
Net Other Financing Charges
-1.13
-986.49%
-0.10
-121.89%
-0.05
+38.71%
-0.08
Changes In Cash
15.92
-58.70%
38.55
+4367.57%
-0.90
+92.54%
-12.11
Effect Of Exchange Rate Changes
0.10
+19589.47%
0.00
+102.94%
-0.02
-382.92%
-0.00
Beginning Cash Position
45.82
+530.55%
7.27
-11.24%
8.19
-59.68%
20.30
End Cash Position
61.83
+34.96%
45.82
+530.55%
7.27
-11.24%
8.19
Free Cash Flow
-12.20
-90.52%
-6.40
+18.50%
-7.86
-8.71%
-7.23
Amortization Of Securities
-0.72
-7846.58%
-0.01
—
—
Common Stock Issuance
127.14
+114.06%
59.40
+2763.59%
2.07
+1797.07%
0.11
Issuance Of Capital Stock
127.14
+114.06%
59.40
+2763.59%
2.07
+1797.07%
0.11
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category